Form D · Pharmaceuticals
Cerium Pharmaceuticals, Inc.
Gaithersburg, MD · CIK 0001677995
Offering snapshot reported Aug 6, 2026 · SEC filing
- Reported sold
- $750K Offering amount: $2.54M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 22, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2026 | Initial | $750,000 | No comparison | 4 | SEC filing |
| Jul 30, 2021 | Initial | $8,900,000 | No comparison | Not reported | SEC filing |
| May 25, 2021 | Initial | $1,905,432 | No comparison | 9 | SEC filing |
| Jun 27, 2016 | Initial | $2,273,681 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-593360
Source: Form D, filed Aug 6, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Collum | Director |
| Thomas A De Pasquale | Director |
| Tom De Pasquale | Director |
| Steve Eskenazi | Director |
| James Gale | Director |
| Nancy Klett | Executive |
| Gregg A. Lapointe | Director, Executive |
| Robert Rubin | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
312 Main Street Suite 300
Gaithersburg, MD, 20878
Gaithersburg, MD, 20878